Info

Cutanea Life Sciences is a development stage specialty pharmaceutical company whose mission is to strategically in-license novel, mid-stage candidates to treat diseased and aging skin conditions, aggressively advance their development and maximize intellectual property and therapeutic applications, in order to create market-leading products for out-license or commercialization. We seek to improve human health and appearance through enterprising initiatives, serving the collective interests of patients and medical professionals. Cutanea is committed to a holistic approach to drug and device development, realizing that maximum value creation emanates from the flawless execution of strategically designed development programs. Cutanea Life Science's core competencies include a team of professionals with more than 90 years of combined experience in developing and commercializing healthcare products. Over the past decade, the individuals comprising this team have played a critical role in securing the US approval and launch of six NDA products, one PMA class three medical device and various international registrations. Specific expertise includes formulation and analytical chemistry, pharmaceutical science, project management, regulatory affairs, quality assurance, clinical development and commercial operations. In addition to our core team, Cutanea is advised by a broad network of technical and commercial experts, as well as practicing physicians and key medical opinion leaders. Cutanea Life Sciences is a member of the family of bio/pharmaceutical companies founded in conjunction with Paramount BioSciences, Inc. This relationship provides the company further access to the resources and support needed to grow a successful drug development company.